In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...
A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...
Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...
Examine how the American Cancer Society’s national ACTS expansion is designed to simplify trial discovery, reduce logistical ...
Funding uncertainty, legal and political pressures, trade policy shifts, site collaboration strategies, and leadership perspectives were central themes across Applied Clinical Trials’ most-watched ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback